Skip to main content

Table 4 Studies involving Linac-SBRT and CK-SBRT for early-stage NSCLC

From: High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study

 

T factor (n)

LC (%)

OS (%)

Dose

Prescription

Lung toxicity

Linac-SBRT

 Timmerman et al. [4]

T1 (44)

3-year: 97.6

3-year: 55.8

54 Gy/3 Fr

PTV D95

Grade 3: 4%

T2 (11)

     

 Nagata et al. [5]

T1 (169)

Operable

Operable

48 Gy/4 Fr

Isocenter

Operable

 

3-year: 85.4

3-year: 76.5

  

Grade 3: 3%

 

Inoperable

Inoperable

  

Inoperable

 

3-year: 87.3

3-year: 59.9

  

Grade 3: 8%

     

Grade 4: 1%

 Koshy et al. [21]

T1 (334)

NA

3-year: 50

48–60 Gy/3–4 Fr

NA

NA

T2 (164)

 

5-year: 30

   

 Matsuo et al. [25]

T1 (73)

3-year: 86.8

3-year: 58.6

48 Gy/4 Fr

Isocenter

Grade 3: 3%

T2 (28)

 

5-year: 46.7

   

CK-SBRT

 Bahig et al. [10]

T1 (123)

2-year: 96

2-year: 87

40–60 Gy/3–5 Fr

PTV D95

Grade 3: 1%

T2 (27)

   

75% isodose

Grade 5: 2% (with IPF)

 Heal et al. [11]

T1 (63)

2-year: 94

3-year: 37

50–60 Gy/3–5 Fr

NA

Grade 3: 2%

T2 (37)

3-year: 84

    

 van der Voort van Zyp et al. [12]

T1 (39)

2-year

1-year: 83

45 or 60 Gy/3 Fr

PTV D95

Grade 3: 4%

T2 (31)

45 Gy: 78

2-year: 62

 

70–85% isodose

 
 

60 Gy: 96

    

 Present study

T1a/b (61)

2-year: 97

2-year: 90

54–60 Gy/3 Fr

GTV D99

Grade 3: 1%

T1c (30)

   

70–80% isodose

 

T2 (5)

     
  1. Linac-SBRT linear accelerator-based stereotactic body radiotherapy, CK-SBRT CyberKnife®-based stereotactic body radiotherapy, NSCLC non-small cell lung carcinoma, PTV planning target volume, NA not available, IPF idiopathic pulmonary fibrosis, GTV gross tumor volume, Fr fractions